The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The KRAS-variant and treatment response in BATTLE-1.
Joanne B. Weidhaas
Employment or Leadership Position - Mira Dx (I,U)
Consultant or Advisory Role - Mira Dx (U)
Stock Ownership - Mira Dx
Edward S. Kim
No relevant relationships to disclose
Roy S. Herbst
No relevant relationships to disclose
Jun Yu
No relevant relationships to disclose
Frank Slack
Consultant or Advisory Role - Mira Dx (U)
Stock Ownership - Mira Dx
George R. Blumenschein
No relevant relationships to disclose
Anne S. Tsao
No relevant relationships to disclose
Ignacio Ivan Wistuba
No relevant relationships to disclose
J. Jack Lee
No relevant relationships to disclose
Vassiliki Papadimitrakopoulou
No relevant relationships to disclose
Waun Ki Hong
No relevant relationships to disclose
John Heymach
No relevant relationships to disclose
Hai T. Tran
No relevant relationships to disclose